Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Abhenil Mittal, Srikala S. Sridhar, Michael Ong, Di Maria Jiang
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2023-04-01
Sarja:	Current Oncology
Aiheet:	metastatic castrate sensitive prostate cancer triplet therapy androgen receptor pathway inhibitors docetaxel abiraterone darolutamide
Linkit:	https://www.mdpi.com/1718-7729/30/4/332
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!